jim, OK kui n.ö. päevikut ei pea, siis kas raha teh.analüüsi alla paned? ja muidugi olulisem küsimus palju aasta keskmine tootlus on?
P.S. ära arva, et ma halvustavalt küsin, tahan lihtsalt teada kuidas lood on, kuna ise pole teh.analüüsi kunagi kasutanud.
Tehvlon: nagu öeldud, püüan ikka jõudumööda jälgida antud ideede käitumist, kuid 5 ideed päevas, see on 25 nädalas ja ca 100 kuus, lihtsalt ei jõua kõigel pidevalt silma peal hoida.
Kuldar1, praegu ei. Mitte et ei usuks tehnilisse analüüsi. Küsimus on selles, et korraliku TA portfelli jaoks oleks vaja pidevalt ca 7-10 ideed käigus hoida, mis nõuab üsna palju energiat ja tähelepanu.
Ardo
Kuldar1, praegu ei. Mitte et ei usuks tehnilisse analüüsi. Küsimus on selles, et korraliku TA portfelli jaoks oleks vaja pidevalt ca 7-10 ideed käigus hoida, mis nõuab üsna palju energiat ja tähelepanu.
Ardo
Fondidest oli üleval juttu, allpool suurimad kaotajad.
Some mutual funds had big concentrations of Merck as of the June 30 reports. Ugh. They include Profunds Ultra Pharmaceuticals , an index fund with almost 10% of assets in Merck; Fidelity's Select Pharma fund with 8%; One Group Health Sciences with 6%; Strong Dow 30 Value with 6%; and Hennessy Total Return with 5.5%.
With Merck down about 25% right now, these funds are looking at losses on that single position of 2.5% to 1.5%. A big caveat is the outdated portfolio information supplied by fund companies. The funds mentioned could have reduced -- or increased -- their stakes since the end of June.
Funds that have unloaded big stakes in Merck this year, as of the end of June, include the Fidelity Contrafund run by Will Danoff and T. Rowe Price's Science and Technology fund run by Michael Sola.
Some mutual funds had big concentrations of Merck as of the June 30 reports. Ugh. They include Profunds Ultra Pharmaceuticals , an index fund with almost 10% of assets in Merck; Fidelity's Select Pharma fund with 8%; One Group Health Sciences with 6%; Strong Dow 30 Value with 6%; and Hennessy Total Return with 5.5%.
With Merck down about 25% right now, these funds are looking at losses on that single position of 2.5% to 1.5%. A big caveat is the outdated portfolio information supplied by fund companies. The funds mentioned could have reduced -- or increased -- their stakes since the end of June.
Funds that have unloaded big stakes in Merck this year, as of the end of June, include the Fidelity Contrafund run by Will Danoff and T. Rowe Price's Science and Technology fund run by Michael Sola.
Kusagil juhtimisteaduses on kirjas, et inimesele ei olegi mõtet pikemas ajahorisonis rohkem eesmärke seada kui 5-7...
... mille peale on omakorda naerdud, et seetõttu jäävad ka piibli 10 käsku täitmata.
... mille peale on omakorda naerdud, et seetõttu jäävad ka piibli 10 käsku täitmata.
Kas MRK on hea straddle proovimiseks [ei salga oma algajalikkust]? Minu arvates võiks olla. Kuhugi ta ju peab liikuma.